Literature DB >> 10583254

p38 MAPK is activated but not necessary in porcine von Willebrand factor-dependent platelet activation.

S Song1, J Freedman, M Mody, A H Lazarus.   

Abstract

We have investigated the role of p38 mitogen-activated protein kinase (MAPK) in von Willebrand factor (VWF)-dependent platelet activation. The interaction of platelets with subendothelial VWF, especially under high shear stress, is considered to be the first activation step which primes platelets for subsequent haemostatic events. As a model of VWF-dependent platelet activation, porcine VWF was employed. Porcine VWF induced p38 MAPK activation by 1 min post-addition; assessed by phosphorylation of a recombinant p38 MAPK fusion protein substrate termed glutathione S-transferase-MAPK activated protein kinase-2. To determine if p38 MAPK was necessary for porcine VWF-induced platelet activation, we functionally inhibited p38 MAPK activity with SB203580 before exposure of the platelets to porcine VWF. Inhibition of p38 MAPK had no effect on VWF-induced platelet alpha or lysozomal granule release, expression of activated GPIIb IIIa, modulation of membrane glycoprotein CD41, expression of phosphatidylserine as assessed by annexin V binding, microparticle formation, or platelet agglutination. It was concluded that SB203580-inhibitable p38 MAPK activity induced by porcine VWF is not necessary for platelet activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10583254     DOI: 10.1046/j.1365-2141.1999.01750.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Bombesin enhances TGF-beta growth inhibitory effect through apoptosis induction in intestinal epithelial cells.

Authors:  Xianghua Liu; Junmei Zhao; Fazhi Li; Yan-shi Guo; Mark R Hellmich; Courtney M Townsend; Yanna Cao; Tien C Ko
Journal:  Regul Pept       Date:  2009-07-23

2.  Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin alphaIIb beta3.

Authors:  Zhenyu Li; Guoying Zhang; Robert Feil; Jiahuai Han; Xiaoping Du
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.